Prognostic value of neurofilament light in blood in patients with polyneuropathy: A systematic review
Journal of the Peripheral Nervous System · 2024
DOI: 10.1111/jns.12608 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of the Peripheral Nervous System, 2024. Verfasst von Louise Sloth Kodal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Neuromuscular Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Polyneuropathies, Charcot-Marie-Tooth Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: jaschafonden.
Abstract (Originalsprache)
Neurofilament light protein (NfL) is a part of the neuronal skeleton, primarily expressed in axons, and is released when nerves are damaged. NfL has been found to be a potential diagnostic biomarker in different types of polyneuropathies. However, whether NfL levels can be used as a predictor for the risk of disease progression is currently less understood. We searched MEDLINE (PubMed), Embase, Cochrane Library, and Web of Science Searches and included longitudinal studies with a baseline and follow‐up examination of adult patients with polyneuropathy and NfL measured in blood. Twenty studies investigating NfL as a predictor of disease progression were identified, examining eight polyneuropathy subtypes. The results from studies in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients were divergent, with two out of five studies finding a significant association between NfL levels and clinical outcomes. Meta‐analysis of the three Guillian‐Barré Syndrome (GBS) studies found higher odds for the inability to run after 1 year in patients with high levels of NfL (odds ratio 2.18, 95% confidence interval 1.04–4.56). Results from studies examining other subacute or chronic polyneuropathies like Charcot–Marie–Tooth (CMT) varied in study design and results. Our findings suggest NfL can be used as a predictor of disease progression, particularly in polyneuropathies such as CIDP and GBS. However, NfL may not serve as a reliable and cost‐effective biomarker for slowly progressive polyneuropathies like CMT. Future standardized studies considering NfL as a prognostic blood biomarker in patients with different types of polyneuropathies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Copenhagen Neuromuscular Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Louise Sloth Kodal
Förderung
- jaschafonden
Zitieren
APA
Kodal, L. S., Witt, A. M., Pedersen, B. S., Aagaard, M. M., & Dysgaard, T. (2024). Prognostic value of neurofilament light in blood in patients with polyneuropathy: A systematic review. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.12608
Vancouver
Kodal LS, Witt AM, Pedersen BS, Aagaard MM, Dysgaard T. Prognostic value of neurofilament light in blood in patients with polyneuropathy: A systematic review. Journal of the Peripheral Nervous System. 2024. doi:10.1111/jns.12608
BibTeX
@article{Kodal2024,
author = {Kodal, Louise Sloth and Witt, Anne Møller and Pedersen, Britt Staevnsbo and Aagaard, Morten Müller and Dysgaard, Tina},
title = {Prognostic value of neurofilament light in blood in patients with polyneuropathy: A systematic review},
journal = {Journal of the Peripheral Nervous System},
year = {2024},
doi = {10.1111/jns.12608}
}
EUVIMED